Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Mezigdomide by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Mezigdomide is under clinical development by Bristol-Myers Squibb and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...